Market capitalization | $572.20m |
Enterprise Value | $309.06m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 34.30 |
P/S ratio (TTM) P/S ratio | 63.51 |
Revenue growth (TTM) Revenue growth | -14.19% |
Revenue (TTM) Revenue | $9.01m |
EBIT (operating result TTM) EBIT | $-208.75m |
As a Free StocksGuide user, you can view scores for all 6,847 stocks worldwide.
11 Analysts have issued a Autolus Therapeutics plc forecast:
11 Analysts have issued a Autolus Therapeutics plc forecast:
Mar '25 |
+/-
%
|
||
Revenue | 9.01 9.01 |
14%
14%
|
|
Gross Profit | -20 -20 |
-
|
|
EBITDA | -201 -201 |
19%
19%
|
EBIT (Operating Income) EBIT | -209 -209 |
19%
19%
|
Net Profit | -180 -180 |
19%
19%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Autolus Therapeutics Plc is a biopharmaceutical company. It engages in the development of cancer treatments. The firm's portfolio includes B Cell Malignancies, Multiple Myeloma, T Cell Lymphoma, GD2+ Tumors, and Prostate Cancer. The company was founded by Martin Pulé in February 2018 and is headquartered in London, the United Kingdom.
Head office | United Kingdom |
CEO | Christian Itin |
Employees | 649 |
Founded | 2014 |
Website | www.autolus.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.